-
Product Insights
Statens Vegvesen – E136 Breivika – Lerstad Road – Troms
Equip yourself with the essential tools needed to make informed and profitable decisions with our Statens Vegvesen - E136 Breivika - Lerstad Road - Troms report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Statens Vegvesen – E10 Nappstraum Tunnel Renovation – Nordland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Statens Vegvesen - E10 Nappstraum Tunnel Renovation - Nordland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Statens Vegvesen – Bomla Bridge And Storda Bridge Improvement – Rogaland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Statens Vegvesen - Bomla Bridge And Storda Bridge Improvement - Rogaland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Statens Vegvesen – E39 Jernfjell and Skrikeberg Tunnel Upgrade – Hordaland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Statens Vegvesen - E39 Jernfjell and Skrikeberg Tunnel Upgrade - Hordaland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
NYCEDC – Staten Island Wind Turbine Facility – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our NYCEDC - Staten Island Wind Turbine Facility - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Statens Vegvesen – S1 Kanebogen-Margrethe Jorgensens via Road – Finnmark Fylke
Equip yourself with the essential tools needed to make informed and profitable decisions with our Statens Vegvesen - S1 Kanebogen-Margrethe Jorgensens via Road - Finnmark Fylke report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Company Profile
Argenx SE – Company Profile
Argenx SE (Argenx) is an immunology company that developed human antibody products for autoimmune diseases. The company's product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118 and ARGX-119. Argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such as ARGX-112, ARGX-114 and ARGX-115. The company develops antibodies using its proprietary technology platforms such as NHance,...
Add to Basket -
Company Profile
Signature Bank – Company Profile
Signature Bank (Signature) offered banking services, through the private client offices located throughout the New York metropolitan area. The bank’s service portfolio includes commercial lending services, wealth management services, asset management services and credit and lending services. Signature also provided services such as investing and brokerage services, cash management services, personal banking accounts services and mortgage services. The bank primarily served privately owned businesses, its owners and senior managers. It had operations in New York metropolitan area, which includes Connecticut,...
Add to Basket -
Product Insights
Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Poliomyelitis Pipeline Drugs Market Report Overview Polio is a highly infectious disease caused by a virus. It invades the nervous system and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio. The Poliomyelitis pipeline drugs market research report provides comprehensive information on the Poliomyelitis targeted therapeutics, complete with analysis by indications, stage of development,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – STT-5058
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry STT-5058 Drug Details STT-5058 (ARGX-116) is under development for the treatment of hypertriglyceridemia. It...